Detailed entry information

Protein Information (annotations from UniProt)

Database IDHIV0002944
UniProt IDO14776
Primary gene name(s)TCERG1
Synonym gene name(s)CA150, TAF2S
Protein nameTranscription elongation regulator 1
Protein functionTranscription factor that binds RNA polymerase II and inhibits the elongation of transcripts from target promoters. Regulates transcription elongation in a TATA box-dependent manner. Necessary for TAT-dependent activation of the human immunodeficiency virus type 1, HIV-1 promoter. {ECO:0000269|PubMed:11604498, ECO:0000269|PubMed:9315662}.
Subcellular locationNucleus {ECO:0000269|PubMed:10908677, ECO:0000269|PubMed:15485897, ECO:0000269|PubMed:9315662}.
ECO codeClick here for more information.
Amino acid sequence
FASTA format: O14776
Gene Ontology
(Biological Process)
Complete annatation
negative regulation of transcription from RNA polymerase II promoter [GO:0000122];
transcription from RNA polymerase II promoter [GO:0006366]
Gene Ontology
(Molecular Function)
Complete annatation
poly(A RNA binding [GO:0044822];
RNA polymerase II repressing transcription factor binding [GO:0001103];
RNA polymerase II transcription corepressor activity [GO:0001106];
transcription coactivator activity [GO:0003713]
Gene Ontology
(Cellular Component)
Complete annatation
actin cytoskeleton [GO:0015629];
nucleolus [GO:0005730];
nucleus [GO:0005634]
Protein-protein interaction116120
Phylogenetic treeO14776
HIV replication factor status Zhou et al., Cell. Host. Microbe., 2008
Brass et al., Science, 2008
Smith et al., J. Immunol, 2010
gene status
Lu et al., J. Virol., 2011
      Folds changes 8h: unknown; Folds changes 16h: unknown; Tested: unknown;
Schoggins JW and Rice CM, Curr. Opin. Virol., 2011
      Targeted viruses: unknown
      Viral life cycle: unknown
      Mechanism related to antiviral activity: unknown
Anti-viral restriction factor Liu et al., Retrovirology, 2011
      unknown (Triplicates)

Gene Expression Profile       top

            Up-regulated;            Down-regulated

For brief introduction to each study, please go to the help page.

Gene expression during HIV latency

(1). Mohammadi et al., PLoS Pathog., 2014

Differentially expressed transcripts (Pairwise) during latency and subsequent viral reactivation using several agents - Primary CD4+ T-cell based model

DMSO: Dimethyl suloxyde (negative control) - 0.0033% final
SAHA: Vorinostat (Histone deacetylase inhibitor) - 0.5 μM
CD3: TCR Stimulation by IL-2+ antiCD3/anti-CD28 antibodies
IL7: Interleukin-7 based stimulation
DISU: Disulfiram (alcohol dehydrogenase inhibitor) - 0.5 μM
AZA: 5-azacytidine (AZA; DNA methylation inhibitor) - 1 μM
Experimental Condition Log2 Fold Change P value Adjusted P value
AZA vs. CD31.202977316784780.0002853805780793640.00121385306070173
AZA vs. DISU-0.08209834399764840.7456013745424330.976008954784031
AZA vs. IL70.2874811313892320.1349827848188280.898662602392564
AZA vs. SAHA-0.2008473638359850.4106314776545710.766166467900112
DISU vs. CD3-1.297982686037180.0004256635093076170.00199108391780774
DISU vs. IL70.3609181194628550.1525555452618470.507676566185949
DISU vs. SAHA-0.1178850679023830.6856450358838770.906929947389411
DMSO vs. AZA0.02107150487622970.8999402514978741
DMSO vs. CD3-1.193261554270730.0002275768694508520.000934435960282661
DMSO vs. DISU0.1015524298095750.6773872841119190.955558024109952
DMSO vs. IL70.2735766358816050.1282312314106320.626104332269861
DMSO vs. SAHA-0.2291713118071980.3313490071482420.685429886016738
HIV vs. Mock in Activation0.03791312874039130.9514043052896740.999983755607037
HIV vs. Mock in Latency-0.02439608515408840.882492312686390.999834320637052
IL7 vs. CD3-0.9072277581422110.005016676066865730.0168111067932119
SAHA vs. CD3-1.429267013371457.1883048160637e-050.000358701170788344
SAHA vs. IL7-0.4924778329634460.04361669757356580.16751034375132
(2). Iglesias-Ussel et al., J. Virol., 2013

Up and Downregulated transcripts during Latency (Latently infected CD4+ T cells vs Uninfected)- Primary CD4+Tcell based model
Log2 Fold Change P Value
unknown unknown

Gene expression during HIV infection and replication

(1). Imbeault et al., PloS Pathog., 2012

Transcriptomic profiling of HIV-1 infected CD4+ T cells - Primary CD4+ T cells
Experiment type Log2 Fold Change P Value Adjusted P Value
Infected vs. Mock unknown unknown unknown
Infected vs. Bystander unknown unknown unknown
(2). Lefebvre et al., J. Virol., 2011

Transcriptome analysis of T-cell line (Sup T1)
Log2 Fold Change unknown
(3). Li et al., J. Immunol., 2013

Lymphatic tissue
Acute Fold Change Acute P Value Asymt Fold Change Asypt P Value AIDS Fold Change AIDS P Value
unknown unknown unknown unknown unknown unknown
(4). Chang et al., MBio., 2011

Transcriptome analysis of T-cell line (Sup T1)

Derived from Sherrill-Mix et al., BMC Retrovirol., 2015 cross validation
Up-regulated (True) FALSE
(5). Sherrill-Mix et al., BMC Retrovirol., 2015

Deep RNA-seq analysis of primary human T cell infected with low passage HIV isolate HIV89.6 - Primary CD4+ T cell based
Test Status Log2 Fold Change P Value
OK 0.422512 0.00154878
(6). Rotger et al., PLoS Pathog., 2010

Genome-wide mRNA expression of CD4+ T cells from HIV-infected patient
(Genes differentially expressed (at adjusted p<0.01) according to the empirical Bayes approach)
Log2 Fold Change P Value
unknown unknown

Proteomic/Transcriptomics studies indicating differentially expressed genes mediated by HIV

(1). Greenwood et al., Elife, 2016

Activated (CD3/CD28) Primary human CD4+ T cells infected with pNL4-3-dE-EGFP. The table shows the complete (unfiltered) TMT (tandem mass tag)-based proteomic time course dataset
6 h 24 h 48 h 72 h RTi
1.035 0.915 0.86 0.856 0.859
(2). Navare et al., Virology, 2012

SUP-T1 cell line
FC-4hpi P-value FC-8hpi P-value FC-20hpi P-value Category
unknown unknown unknown unknown unknown unknown unknown
(3). Hyrcza et al., J. Virolo., 2007

Primary human CD4+ and CD8+ T Cells
Affymetrix Prob ID Fold Change In CD8? Category
unknown unknown unknown unknown

Protein Overview       top

Drug-protein Interaction       (annotations from DrugBank)      top

not found

Protein Secondary Structure       (annotations from PDB)      top

PDB Accession Method Resolution Chain Structure Preview
2DK7 NMR - A=520-579.
2DOD NMR - A=651-719.
2DOE NMR - A=784-853.
2DOF NMR - A=888-959.
2E71 NMR - A=717-786.
2KIQ NMR - A=724-782.
2KIS NMR - A=659-724.
2MW9 NMR - A=428-464.
2MWA NMR - A=428-464.
2MWB NMR - A=428-464.
2MWD NMR - A=433-460.
2MWE NMR - A=433-460.
2MWF NMR - A=433-464.
2N4R NMR - A=428-464.
2N4S NMR - A=428-464.
2N4T NMR - A=428-464.
2N4U NMR - A=428-464.
2N4V NMR - A=428-464.
2N4W NMR - A=428-464.
2NNT NMR - A/B/C/D=428-464.
3HFH X-ray 2.7Å A/B=661-845.
3Q1I X-ray 1.4Å E=99-107.
4FQG X-ray 2.0Å A/B=895-1081.

HIV-1 Interaction       (annotations from NCBI HIV-1 Interaction Database)      top

HIV Partner Interaction Type PubMed
Tat associates with 19966273

Metabolic/Signalling Pathway       (annotations from KEGG database)      top

Pathway Accession Number Description
hsa03040 Spliceosome - Homo sapiens (human)